Results 151 to 160 of about 117,898 (292)

Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib [PDF]

, 2018
Joshua B. Brown, Reetesh K. Pai, Melissa Burgess, Jennifer Chennat, Amer H. Zureikat   +4 more
openalex   +1 more source

Nanobiotechnology‐Based Approaches for Targeted Glioma Therapy

Advanced NanoBiomed Research, Volume 6, Issue 1, January 2026.
Nanoparticle systems cross the blood–brain barrier to deliver drugs precisely to glioma cells. Lipid, polymeric, and magnetic carriers enable controlled release, tumor targeting, and microenvironment modulation. These nanoplatforms enhance chemotherapy, radiotherapy, and immunotherapy, improving therapeutic efficacy while reducing systemic toxicity ...
Jinwei Li, Yibo He, Yang Zhang, Lining Arnold Ju, Yao Wang, Jianxuan Zhou, Yinying Chai, Xuhui Hui, ShiYuan Tong, Si Zhang, Yanli Tan, Yinyan Wang   +11 more
wiley   +1 more source

New Quinoline Kinase Inhibitors With Good Selectivity for NAK Kinases and Anti‐Tumor Activity Against Ewing Sarcoma

Archiv der Pharmazie, Volume 359, Issue 1, January 2026.
Focusing on the discovery of new therapeutics for childhood cancer, novel quinoline derivatives were synthesized and demonstrated activity against Ewing sarcoma. A target search was performed against a panel of kinases, and the compounds showed selectivity for the NAK family, mainly GAK, which was confirmed by enzyme kinetic assays.
Caroline de Bem Gentz, Thais Helena Maciel Fernandes, Marcela Silva Lopes, Lewis Elson, Andreas Krämer, Lucas Rodrigo de Souza, Isadora Serraglio Fortes, Geórgia Silva Pinto, Martha Cestari Silva Martins, Henrique Barros de Lima, André da Silva Santiago, Lauro José Gregianin, Katlin Brauer Massirer, Mário Henrique Bengtson, Rafael Roesler, Stefan Knapp, Stefan A. Laufer, Saulo Fernandes de Andrade   +17 more
wiley   +1 more source

Gilteritinib in an Isolated CNS Recurrence of FLT3‐ITD Positive AML

Clinical Case Reports, Volume 14, Issue 1, January 2026.
Time course showing changes in cell count and FLT3‐ITD ratio in cerebrospinal fluid (CSF) from diagnosis through treatment. ABSTRACT Central nervous system (CNS) involvement in adult acute myeloid leukemia (AML) is uncommon and more frequently observed at relapse than at initial presentation.
Lina Susana Silva‐Bermudez, Alexander Streuer, Foteini Christodoulou, Philipp Eisele, Laurenz Steiner, Georgia Metzgeroth, Michael Platten, Wolf‐Karsten Hofmann, Mohammed L. Abba   +8 more
wiley   +1 more source

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial [PDF]

, 2011
Aurore Blesius, Philippe A. Cassier, François Bertucci, Jérôme Fayette, Isabelle Ray‐Coquard, Binh Bui, Antoine Adenis, María Rios, Didier Cupissol, David Pérol, Jean‐Yves Blay, Axel Le Cesne   +11 more
openalex   +1 more source

Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107

, 2008
Meir Wetzler, Kathleen Donohue, Olatoyosi Odenike, Eric J. Feldman, David D. Hurd, Richard M. Stone, Peter Westerfelt, Clara D. Bloomfield, Richard A. Larson   +8 more
openalex   +1 more source

A Case Report of Imatinib-induced Acute Heart Failure and Literature Review

, 2022
Zhaodong Li, Wen Qü, Xiaolin He, Xinhua Zhao, Yujun Luo, Jinhong Wang   +5 more
openalex   +2 more sources

Melanoma: Pathogenesis and Targeted Therapy

MedComm, Volume 7, Issue 1, January 2026.
The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu, Jie Liu, Zeming Mo, Bin Wang, Yaotiao Deng, Yu Jiang   +5 more
wiley   +1 more source

Supplemental Table 1 from Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors

, 2023
Sébastien Grosso, Alexandre Puissant, Maeva Dufies, Pascal Colosetti, Arnaud Jacquel, Kévin Lebrigand, Pascal Barbry, Marcel Deckert, Jill Patrice Cassuto, Bernard Mari, Patrick Auberger   +10 more
openalex   +1 more source

Piperazine Derivatives: A Privileged Scaffold in Modern Synthesis and Medicinal Chemistry

ChemistryOpen, Volume 15, Issue 1, January 2026.
Piperazine‐based bioactive molecules represent a versatile class of compounds with broad therapeutic potential. Structural modification of the piperazine scaffold governs key structure–activity relationships, enabling antibacterial, antifungal, antitumor, neuroactive, and anti‐inflammatory activities.
Assel Ten, Raushan Koizhaiganova, Dilnaz Bissenbay, Bagila Tursynova, Zhanar Zhaxibayeva, Valentina Yu   +5 more
wiley   +1 more source